Ilina C. Odouard

Aug 30, 2024 | jamanetwork.com | Jenny M. Markell |Ilina C. Odouard |Gerard F. Anderson |Michael J. DiStefano

Introduction The US Food and Drug Administration (FDA) requires that direct-to-consumer advertising (DTCA) describe a drug’s benefits and risks in a balanced way and recommends presenting effectiveness and risk information quantitatively to improve consumer comprehension.1,2 Print product-claim advertisements must include a brief summary of all risks, but there is no requirement that every risk be prominently presented or severe risks be highlighted.3 Presentation of risk information in DTCA...

Sep 27, 2023 | jamanetwork.com | Mariana P. Socal |Gerard F. Anderson |Emily Harris |Ilina C. Odouard

An amyloid-directed monoclonal antibody, lecanemab-irmb (Leqembi), was approved by the US Food and Drug Administration (FDA) on July 6, 2023, to treat Alzheimer disease with mild cognitive impairment or mild dementia.